<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731623</url>
  </required_header>
  <id_info>
    <org_study_id>ION904-CS1</org_study_id>
    <nct_id>NCT04731623</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending, Dose-Escalation, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904 Administered Subcutaneously to Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of ION904.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose&#xD;
      escalation study of ION904 in up to 72 participants. Following a Screening Period of up to 28&#xD;
      days, eligible healthy participants will be randomized to treatment and receive a single,&#xD;
      subcutaneous (SC) dose of the assigned study drug. Participants will be followed for up to 13&#xD;
      weeks after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity and dose relationship of TEAE</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity and dose relationship of clinically significant changes in laboratory values</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity and dose relationship of clinically significant changes in ECG</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Level of ION904 Target Biomarker</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration of ION904</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration of ION904</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½λz: Plasma Elimination Half-life of ION904</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t for ION904</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine 0-24 Hour (hr) Excretion of ION904</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ION904</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose of ION904 will be administered by SC injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% sterile saline) will be administered by SC injection on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ION904</intervention_name>
    <description>ION904 will be administered by SC injection.</description>
    <arm_group_label>ION904</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (0.9% sterile saline) will be administered by SC injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be healthy males, or females of non-childbearing potential, aged 18 to 65 at the&#xD;
             time of informed consent&#xD;
&#xD;
          2. Females must be either surgically sterile or post-menopausal; males must be abstinent,&#xD;
             surgically sterile, or if engaged in sexual relations with a woman of childbearing&#xD;
             potential, a highly effective contraceptive method must be used from the time of&#xD;
             signing the informed consent form until at least 13 weeks after the last dose of Study&#xD;
             Drug or the healthy participant must be abstinent through this time period&#xD;
&#xD;
          3. Willing to refrain from strenuous exercise/activity (for example heavy lifting, weight&#xD;
             training, intense aerobics classes etc.) for at least 24 hours prior to study visits&#xD;
&#xD;
          4. Body mass index (BMI) requirements between 18 and 35 kg/m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormalities in medical history or physical examination&#xD;
&#xD;
          2. Uncontrolled arterial hypertension&#xD;
&#xD;
          3. Active infection with human immunodeficiency virus (HIV), hepatitis C or hepatitis B&#xD;
             or prior treatment for hepatitis C&#xD;
&#xD;
          4. Treatment with another investigational drug, biological agent, or device within 1&#xD;
             month of Screening&#xD;
&#xD;
          5. History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          6. Regular use of alcohol within 6 months prior to screening, or use of soft drugs within&#xD;
             3 months prior to Screening, or hard drugs within 1 year prior to Screening, or&#xD;
             positive urine drug screen at Screening&#xD;
&#xD;
          7. History of any severe (e.g., anaphylaxis) drug allergies&#xD;
&#xD;
          8. History of hypersensitivity to other antisense oligonucleotides (ASOs)&#xD;
&#xD;
          9. Concomitant medication restrictions: over-the-counter or prescription medications&#xD;
             within 14 days, prior to dosing on Day 1. Accepted exceptions are:&#xD;
&#xD;
               -  Acetaminophen (paracetamol) up to 2 grams per day (g/d) or ibuprofen up to 2.4&#xD;
                  g/day taken sporadically for analgesia&#xD;
&#xD;
               -  Thyroid hormone replacement therapy provided participant is stable on replacement&#xD;
                  therapy (and participant is euthyroid)&#xD;
&#xD;
               -  Other possible exceptions must be reviewed and acknowledged by the Investigator&#xD;
                  in consultation with Sponsor's Medical Monitor&#xD;
&#xD;
         10. Blood donation of 50 to 499 mL within 30 days of Screening or of &gt; 499 mL within 60&#xD;
             days of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BioPharma Services, Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Participants</keyword>
  <keyword>Hypertension</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

